當(dāng)前位置：   首頁(yè) > 需求大廳

求拜耳愛(ài)沃克《吡蟲啉莫昔克丁滴劑（貓用）質(zhì)量標(biāo)準(zhǔn)》、《吡蟲啉莫昔克丁滴劑（犬用）質(zhì)量標(biāo)準(zhǔn)》。 具體需求：農(nóng)業(yè)農(nóng)村部公告第173號(hào)公布的“吡蟲啉莫昔克丁滴劑（貓用）”、“吡蟲啉莫昔克丁滴劑（犬用）” 質(zhì)量標(biāo)準(zhǔn)。要求時(shí)間：請(qǐng)?jiān)?021年10月31日前發(fā)給我。交稿方式：直接點(diǎn)擊交稿，在線交稿就行。如果價(jià)格不合適，可以聯(lián)系我。謝謝！農(nóng)業(yè)農(nóng)村部公告 第173號(hào).pdf   [更多]

擬并購(gòu)醫(yī)藥企業(yè)要求：化藥或生物制藥企業(yè)生產(chǎn)企業(yè)（產(chǎn)品不含醫(yī)療器械）；地理位置處于省會(huì)城市（北方邊疆省份、東北堅(jiān)決不去）、南方經(jīng)濟(jì)發(fā)達(dá)省份省會(huì)城市和地級(jí)均也可接受，西安市地區(qū)更佳；資產(chǎn)狀況良好，經(jīng)營(yíng)正常；GMP車間在有效期內(nèi)；年度營(yíng)收在5000萬(wàn)到5億之間，凈利在100萬(wàn)到3000萬(wàn)之間；主要單品收入不低于5000萬(wàn)元；一致性評(píng)價(jià)工作取得實(shí)質(zhì)性進(jìn)展。 加分項(xiàng)：擁有滴眼液生產(chǎn)線；獨(dú)家品種；主要產(chǎn)品與多肽相關(guān)。 擬并購(gòu)股權(quán)比例：最低51%，現(xiàn)金收購(gòu)。 提供有效聯(lián)系方式可獲得賞金   [更多]

質(zhì)量標(biāo)準(zhǔn)/進(jìn)口注冊(cè)標(biāo)準(zhǔn)中需有對(duì)氨基酸和短肽類較為詳細(xì)的測(cè)定方法，不限劑型（最好有較詳細(xì)的色譜條件、對(duì)照品選擇及質(zhì)控限度）   [更多]

求購(gòu)Good Clinical Practice:A Question& Answer Reference Guide2024/2025(Electronic)   [更多]

Resveratrol.（白黎蘆醇）《EP9.1》的藥典中標(biāo)準(zhǔn)一份   [更多]

2元一篇   [更多]

題目： Lyoc (Lyophilized Wafer): An orally disintegrating tablet technology 作者 ：S Fulzele ， D Moe ， E Hamed 出版源 《Drug Dev Del》 , 2012 鏈接 http://xueshu.baidu.com/s?wd=Lyoc+%28Lyophilized+Wafer%29%3A+An+orally+disintegrating+tablet+technology&rsv_bp=0&tn=SE_baiduxueshu_c1gjeupa&rsv_spt=3&ie=utf-8&f=8&rsv_sug2=0&sc_f_para=sc_tasktype%3D%7BfirstSimpleSearch%7D&rsv_n=2   [更多]

1.Bulletin of the Chemical Society of Japan, Volume 26, Pages 119-122, Journal, 1953 2.Dalton Transactions 2017,vol. 46, # 5, p. 1510 - 1519 3.Design and evaluation of ophthalmic pharmaceutical products. In Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 4th edn. New York Marcel Dekker, 2002 415-478 4.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer 5.Journal of Photochemistry and Photobiology, B Biology, Volume 97, Issue 1, Pages 18-21, Journal, 2009 6.Journal of Photochemistry and Photobiology, B Biology, Volume 115, Pages 51-57, Journal; Online Computer File, 2012 7.Nair AD, Lach JL. The kinetics of degradation of chlorobutanol. J Am Pharm Assoc (Sci) 1959; 48 390-395. 8.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine 9.Plasma?renin?activity-guided strategy for the management of hypertension. 10.Stability of chlorobutanol in aqueous solutions Journal of the American Pharmaceutical Association (1961), Volume 6, Issue 7, July 1966, Pages 372-373 11.Talanta, Volume 146, Pages 732-736, Journal; Online Computer File, 2016   [更多]

標(biāo)題： 1.Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men 作者：Azuma, Junichi 1;Fukase, Hiroyuki 2 刊名：Clinical Pharmacology in Drug Development 出版日期：2013 期號(hào)：No.4 卷號(hào)：Vol.2 2.Pharmacokinetic evaluation of fosaprepitant dimeglumine 作者：Colon-Gonzalez F;Kraft WK. 刊名：Expert Opinion on Drug Metabolism and Toxicology 出版日期：2010 期號(hào)：No.10 卷號(hào)：Vol.6 3.Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects 作者：Dr Thomas C. Marbury MD1,*;Ms Phung L. Ngo MS2;Mr Craig R. Shadle MS2;Dr Bo Jin PhD2;Ms Deborah Panebianco MS2;Dr Luzelena Caro PhD2;Dr Jack Valentine PhD2,3;Dr Gail Murphy MD2 刊名：J Clin Pharmacol 出版日期：2011 卷號(hào)：Vol.51 4.A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects 作者：Craig R. Shadle1,*;M. Gail Murphy1;Yang Liu2;Maureen Ho1;Daniel Tatosian3;Susie (Xiujiang) Li3;Robert A. Blum4 刊名：Clinical Pharmacology in Drug Development 出版日期：2012 期號(hào)：No.3 卷號(hào)：Vol.1 5.Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy 作者：Bernardo Rapoport;Teresa Smit 刊名：Expert Opinion on Drug Safety 6.Aprepitant and Fosaprepitant Drug Interactions: A Systematic Review. 作者：Patel P;Leeder JS;Piquette-Miller M;Dupuis LL. 刊名：Br J Clin Pharmacol 出版日期：2017 7.Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. 作者：Dr Kenneth C. Lasseter MD1,*;Dr Jay Gambale PharmD2;Dr Bo Jin PhD2;Dr Art Bergman PhD2;Mr Marvin Constanzer MS2;Mr James Dru MS2;Dr Tae H. Han PhD2;Dr Anup Majumdar PhD2;Dr Judith K. Evans MD2;Dr M. Gail Murphy MD2 刊名：The Journal of Clinical Pharmacology 出版日期：2007 期號(hào)：NO.7 卷號(hào)：Vol.47 8.Prevention of chemotherapy-induced nausea and vomiting:focus on fosaprepitant 作者：Ian N Olver 刊名：Ther Clin Risk Manag 出版日期：2008 期號(hào)：No.2 卷號(hào)：Vol.4   [更多]

收集了全國(guó)各省市的藥品中標(biāo)信息，為了保證給大家有更準(zhǔn)確及時(shí)的信息，需要 對(duì)藥品中標(biāo)信息數(shù)據(jù)庫(kù)及時(shí)更新，現(xiàn)請(qǐng)人進(jìn)行最新中標(biāo)數(shù)據(jù)的收集整理。 工作內(nèi)容：補(bǔ)充2019年8月-2020年1月（共6個(gè)月）公布的藥品中標(biāo)信息，并將最新的文件按指定要求 處理成規(guī)范的格式(excel表)。   [更多]